Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2340)
All Articles published online
|
Feb 14, 2007 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13(6): 837-844 [PMID: 17352011 DOI: 10.3748/wjg.v13.i6.837] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i6/837.htm |
| Number | Citing Articles |
| 1 |
Ciaran E. Fealy, Jacob M. Haus, Thomas P. J. Solomon, Mangesh Pagadala, Chris A. Flask, Arthur J. McCullough, John P. Kirwan. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. Journal of Applied Physiology 2012; 113(1): 1 doi: 10.1152/japplphysiol.00127.2012
|
| 2 |
Ludmila V. Topchieva, Irina V. Kurbatova, Olga P. Dudanova, Alina V. Vasileva, Galina A. Zhulai. Immune cell balance as potential biomarker of progressing non-alcoholic fatty liver disease. Genes & Cells 2024; 19(1): 105 doi: 10.17816/gc610252
|
| 3 |
Carolina F. M. G. Pimentel, Zhenghui G. Jiang, Takeshi Otsubo, Linda Feldbrügge, Tracy L. Challies, Imad Nasser, Simon Robson, Nezam Afdhal, Michelle Lai. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Digestive Diseases and Sciences 2016; 61(3): 905 doi: 10.1007/s10620-015-3916-1
|
| 4 |
Yusuke Kawamura, Kenji Ikeda, Yasuji Arase, Shunichiro Fujiyama, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada. New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Internal Medicine 2017; 56(12): 1459 doi: 10.2169/internalmedicine.56.7830
|
| 5 |
Zixiong Zhou, Jong Won Kim, Jing Zhao, Jing Qi, Seong Jin Choi, Chae Woong Lim, Moo-Yeol Lee, Kyuhong Lee, Bumseok Kim. Treatment of cigarette smoke extract and condensate differentially potentiates palmitic acid-induced lipotoxicity and steatohepatitis in vitro. Toxicology in Vitro 2018; 52: 33 doi: 10.1016/j.tiv.2018.05.017
|
| 6 |
Fatih Eren, Ramazan Kurt, Fatih Ermis, Ozlen Atug, Nese Imeryuz, Yusuf Yilmaz. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clinical Biochemistry 2012; 45(9): 655 doi: 10.1016/j.clinbiochem.2012.03.019
|
| 7 |
Lei He, Linfeng Deng, Quan Zhang, Jianli Guo, Jinan Zhou, Wenjian Song, Fahu Yuan. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/9729107
|
| 8 |
Cristina Macía, Jose Loureiro, Isabel Campos-Varela, Ihab Abdulkader, Esteban Otero, Evaristo Varo, Santiago Tomé, Arturo Gonzalez-Quintela, Ned Snyder. Time-Course Changes of Serum Keratin Concentrations after Liver Transplantation: Contrasting Results of Keratin-18 and Keratin-19 Fragments. Case Reports in Hepatology 2020; 2020: 1 doi: 10.1155/2020/8895435
|
| 9 |
Sercan Kaya, Murat Boydak, Mesut Aydin, İbrahim Aras. Association between serum cytokeratin 18 and N-terminal procollagen III propeptide in patients with biopsy-proven nonalcoholic fatty liver disease*. Biotechnic & Histochemistry 2024; : 1 doi: 10.1080/10520295.2024.2385011
|
| 10 |
Constantinos Simopoulos, Alexandra K Tsaroucha, Byron Asimakopoulos, Alexandra Giatromanolaki, Paschalis Gavriilidis, Alexandros Polychronidis, Anastasios Karayiannakis. Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: A prospective study. BMC Gastroenterology 2008; 8(1) doi: 10.1186/1471-230X-8-14
|
| 11 |
Yvonne Alt, Anna Grimm, Liesa Schlegel, Annette Grambihler, Jens M. Kittner, Jörg Wiltink, Peter R. Galle, Marcus A. Wörns, Jörn M. Schattenberg, Matias A Avila. The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. PLOS ONE 2016; 11(3): e0151200 doi: 10.1371/journal.pone.0151200
|
| 12 |
Arun Sanyal, Kenneth Cusi, Mark L Hartman, Shuyu Zhang, Edward J Bastyr, Juliana M Bue-Valleskey, Annette M Chang, Axel Haupt, Scott J Jacober, Robert J Konrad, Qianyi Zhang, Byron J Hoogwerf. Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. Journal of Investigative Medicine 2018; 66(3): 661 doi: 10.1136/jim-2017-000609
|
| 13 |
Naim Alkhouri, Christine Carter-Kent, Ariel E Feldstein. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Review of Gastroenterology & Hepatology 2011; 5(2): 201 doi: 10.1586/egh.11.6
|
| 14 |
Leon A ADAMS, Ariel E FELDSTEIN. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. Journal of Digestive Diseases 2011; 12(1): 10 doi: 10.1111/j.1751-2980.2010.00471.x
|
| 15 |
Dawn M. Torres, Stephen A. Harrison. Diagnosis and Therapy of Nonalcoholic Steatohepatitis. Gastroenterology 2008; 134(6): 1682 doi: 10.1053/j.gastro.2008.02.077
|
| 16 |
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_32-1
|
| 17 |
Zobair M. Younossi, Mohammed Jarrar, Clare Nugent, Manpreet Randhawa, Mariam Afendy, Maria Stepanova, Nila Rafiq, Zachary Goodman, Vikas Chandhoke, Ancha Baranova. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). Obesity Surgery 2008; 18(11): 1430 doi: 10.1007/s11695-008-9506-y
|
| 18 |
N. J. BARSHOP, C. B. SIRLIN, J. B. SCHWIMMER, J. E. LAVINE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008; 28(1): 13 doi: 10.1111/j.1365-2036.2008.03703.x
|
| 19 |
Fataneh Amidi, Barbara A. French, David Chung, Charles H. Halsted, Valentina Medici, Samuel W. French. M-30 and 4HNE are sequestered in different aggresomesin the same hepatocytes. Experimental and Molecular Pathology 2007; 83(3): 296 doi: 10.1016/j.yexmp.2007.09.001
|
| 20 |
Giovanni Musso, Roberto Gambino, Giovanni Pacini, Franco De Michieli, Maurizio Cassader. Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. The American Journal of Clinical Nutrition 2009; 89(2): 558 doi: 10.3945/ajcn.2008.26720
|
| 21 |
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017; : 603 doi: 10.1007/978-94-007-7675-3_32
|
| 22 |
Y. YILMAZ. Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacology & Therapeutics 2009; 30(11-12): 1103 doi: 10.1111/j.1365-2036.2009.04148.x
|
| 23 |
Krishna Sumanth Nallagangula, Shashidhar Kurpad Nagaraj, Lakshmaiah Venkataswamy, Muninarayana Chandrappa. Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression. Future Science OA 2018; 4(1) doi: 10.4155/fsoa-2017-0083
|
| 24 |
Franck Brouillard, Janine Fritsch, Aleksander Edelman, Mario Ollero. Contribution of proteomics to the study of the role of cytokeratins in disease and physiopathology. PROTEOMICS – Clinical Applications 2008; 2(2): 264 doi: 10.1002/prca.200780018
|
| 25 |
J. Shen, H. L.‐Y. Chan, G. L.‐H. Wong, A. W.‐H. Chan, P. C.‐L. Choi, H.‐Y. Chan, A. M.‐L. Chim, D. K.‐W. Yeung, J. Yu, W. C.‐W. Chu, V. W.‐S. Wong. Assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology & Therapeutics 2012; 36(11-12): 1057 doi: 10.1111/apt.12091
|
| 26 |
Nafiseh Esmaeil, Behjat Moayedi, Marjan Gharagozloo, Mohamad Reza Maracy. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, In Patients with β-Thalassemia Major. Hemoglobin 2013; 37(4): 404 doi: 10.3109/03630269.2013.790828
|
| 27 |
Yusuf Yilmaz, Ramazan Kurt, Cem Kalayci. Apoptosis in Nonalcoholic Steatohepatitis With Normal Aminotransferase Values: Zooming in on Cytokeratin 18 Fragments. Biomarkers in Medicine 2010; 4(5): 743 doi: 10.2217/bmm.10.65
|
| 28 |
J. Shen, V. W.‐S. Wong. Letter: diagnostic accuracy of M30 levels for identifying patients with non‐alcoholic steatohepatitis – authors’ reply. Alimentary Pharmacology & Therapeutics 2013; 37(2): 283 doi: 10.1111/apt.12156
|
| 29 |
Michael H. Miller, Michael A. J. Ferguson, John F. Dillon. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver International 2011; 31(4): 461 doi: 10.1111/j.1478-3231.2011.02451.x
|
| 30 |
Yusuf Yilmaz. Cytokeratins in hepatitis. Clinica Chimica Acta 2011; 412(23-24): 2031 doi: 10.1016/j.cca.2011.09.002
|
| 31 |
Leon A Adams, Ariel E Feldstein. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Review of Gastroenterology & Hepatology 2010; 4(5): 623 doi: 10.1586/egh.10.56
|
| 32 |
Naim Alkhouri, Anna Alisi, Vera Okwu, Ammar Matloob, Federica Ferrari, Annalisa Crudele, Rita De Vito, Rocio Lopez, Ariel E. Feldstein, Valerio Nobili. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2015; 60(8): 2353 doi: 10.1007/s10620-015-3614-z
|
| 33 |
Ying Shi, Shihui Sun, Yali Liu, Junfeng Li, Tong Zhang, Hao Wu, Xinyue Chen, Dexi Chen, Yusen Zhou. Keratin 18 phosphorylation as a progression marker of chronic hepatitis B. Virology Journal 2010; 7(1) doi: 10.1186/1743-422X-7-70
|
| 34 |
Engin Ulukaya, Ceyda Acilan, Yusuf Yilmaz. Apoptosis: why and how does it occur in biology?. Cell Biochemistry and Function 2011; 29(6): 468 doi: 10.1002/cbf.1774
|
| 35 |
Salvatore Petta, Aurora Giannetti. Non-Alcoholic Fatty Liver Disease. 2020; : 235 doi: 10.1007/978-3-319-95828-6_13
|
| 36 |
Ciro Celsa, Grazia Pennisi, Federica Spatola, Aurora Giannetti, Salvatore Petta. NAFLD and NASH. 2020; : 89 doi: 10.1007/978-3-030-37173-9_6
|
| 37 |
Yasar Colak, Ebubekir Senates, Oguzhan Ozturk, Yusuf Yilmaz, Ebru Zemheri, Feruze Yilmaz Enc, Celal Ulasoglu, Sebahat Aksaray, Sabriye Gulcin Bozbeyoglu, Safak Kiziltas, Oya Ovunc Kurdas, Ilyas Tuncer. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2012; 24(3): 255 doi: 10.1097/MEG.0b013e32834e8041
|
| 38 |
Jenny Lee, Yasaman Vali, Jérôme Boursier, Kevin Duffin, Joanne Verheij, M. Julia Brosnan, Koos Zwinderman, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad Hadi Zafarmand, Pavel Strnad. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLOS ONE 2020; 15(9): e0238717 doi: 10.1371/journal.pone.0238717
|
| 39 |
Davide Festi, Ramona Schiumerini, Giovanni Marasco, Eleonora Scaioli, Francesca Pasqui, Antonio Colecchia. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015; 9(8): 1039 doi: 10.1586/17474124.2015.1049155
|
| 40 |
Vaishali Patel, Arun J. Sanyal, Richard Sterling. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2): 277 doi: 10.1016/j.cld.2015.10.006
|
| 41 |
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156(5): 1264 doi: 10.1053/j.gastro.2018.12.036
|
| 42 |
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments. Obesity Surgery 2008; 18(11): 1507 doi: 10.1007/s11695-008-9639-z
|
| 43 |
Julien Calderaro, Elie Serge Zafrani. Stéatopathie hépatique non alcoolique. Annales de Pathologie 2010; 30(6): 413 doi: 10.1016/j.annpat.2010.10.002
|
| 44 |
Yusuf Yilmaz, Fatih Eren. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clinica Chimica Acta 2012; 414: 154 doi: 10.1016/j.cca.2012.08.005
|
| 45 |
Scott C. Beeman, Joel R. Garbow. Imaging and Metabolism. 2018; : 223 doi: 10.1007/978-3-319-61401-4_10
|
| 46 |
Mayumi TABUCHI, Kayoko TOMIOKA, Takayo KAWAKAMI, Yasuko MURAKAMI, Makoto HIRAMATSU, Tatsuya ITOSHIMA, Shiori SUGAWARA, Aiko KAWASHIMA, Misako OKITA, Ikuyo TSUKAMOTO. Serum Cytokeratin 18 M30 Antigen Level and Its Correlation with Nutritional Parameters in Middle-Aged Japanese Males with Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Nutritional Science and Vitaminology 2010; 56(5): 271 doi: 10.3177/jnsv.56.271
|
| 47 |
Juan Pablo Arab, Cristián Hernández-Rocha, Carolina Morales, José Ignacio Vargas, Nancy Solís, Margarita Pizarro, Camila Robles, Daniela Sandoval, Simon Ponthus, Carlos Benítez, Francisco Barrera, Alejandro Soza, Arnoldo Riquelme, Marco Arrese. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. Gastroenterología y Hepatología (English Edition) 2017; 40(6): 388 doi: 10.1016/j.gastre.2017.02.003
|
| 48 |
Jun Yu, Jiayun Shen, Ting Ting Sun, Xiang Zhang, Nathalie Wong. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Seminars in Cancer Biology 2013; 23(6): 483 doi: 10.1016/j.semcancer.2013.07.003
|
| 49 |
Billur Canbakan, Hakan Senturk, Mustafa Canbakan, Tayfur Toptas, Omur Tabak, Huriye Balci, Vakur Olgac, Gulsen Ozbay. Is Alanine Aminotransferase Level a Surrogate Biomarker of Hepatic Apoptosis in Nonalcoholic Fatty Liver Disease?. Biomarkers in Medicine 2010; 4(2): 205 doi: 10.2217/bmm.09.88
|
| 50 |
Mariana V. Machado, Helena Cortez-Pinto. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology 2013; 58(5): 1007 doi: 10.1016/j.jhep.2012.11.021
|
| 51 |
|
| 52 |
Juan Pablo Arab, Cristián Hernández-Rocha, Carolina Morales, José Ignacio Vargas, Nancy Solís, Margarita Pizarro, Camila Robles, Daniela Sandoval, Simon Ponthus, Carlos Benítez, Francisco Barrera, Alejandro Soza, Arnoldo Riquelme, Marco Arrese. Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilena. Gastroenterología y Hepatología 2017; 40(6): 388 doi: 10.1016/j.gastrohep.2017.02.009
|
| 53 |
Jacquelyn J. Maher, Pablo Leon, James C. Ryan. Beyond insulin resistance. Hepatology 2008; 48(2): 670 doi: 10.1002/hep.22399
|
| 54 |
Nora Anderson, Jürgen Borlak. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacological Reviews 2008; 60(3): 311 doi: 10.1124/pr.108.00001
|
| 55 |
Tunay Senturk, Ali Aydinlar, Yusuf Yilmaz, Arzu Yilmaztepe Oral, Osman Ozdabakoglu, Engin Ulukaya. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. Coronary Artery Disease 2009; 20(8): 494 doi: 10.1097/MCA.0b013e328330d56a
|
| 56 |
Julia Kälsch, Lars P. Bechmann, Hagen Kälsch, Martin Schlattjan, Jochen Erhard, Guido Gerken, Ali Canbay. Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. Journal of Nutrition and Metabolism 2011; 2011: 1 doi: 10.1155/2011/369168
|
| 57 |
Pamela Valva, Paola Casciato, Carol Lezama, Marcela Galoppo, Adrián Gadano, Omar Galdame, María Cristina Galoppo, Eduardo Mullen, Elena De Matteo, María Victoria Preciado, Ravi Jhaveri. Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children. PLoS ONE 2013; 8(1): e53519 doi: 10.1371/journal.pone.0053519
|
| 58 |
K Widhalm, E Ghods. Nonalcoholic fatty liver disease: a challenge for pediatricians. International Journal of Obesity 2010; 34(10): 1451 doi: 10.1038/ijo.2010.185
|
| 59 |
Briohny W. Smith, Leon A. Adams. Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences 2011; 48(3): 97 doi: 10.3109/10408363.2011.596521
|
| 60 |
Wah-Kheong Chan, Pavai Sthaneshwar, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Anna Alisi. Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers. PLoS ONE 2014; 9(9): e105903 doi: 10.1371/journal.pone.0105903
|
| 61 |
Pamela Valva, Daniela A Ríos, Elena De Matteo, Maria V Preciado. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World Journal of Gastroenterology 2016; 22(4): 1367-1381 doi: 10.3748/wjg.v22.i4.1367
|
| 62 |
Alastair Greystoke, Andrew Hughes, Malcolm Ranson, Caroline Dive, Jeff Cummings, Tim Ward. Serum biomarkers of apoptosis. European Journal of Cancer Supplements 2007; 5(5): 115 doi: 10.1016/S1359-6349(07)70032-0
|
| 63 |
Rabia Ergelen, Umit Akyuz, Yucel Aydin, Fatih Eren, Yusuf Yilmaz. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2015; 27(6): 667 doi: 10.1097/MEG.0000000000000342
|
| 64 |
Sophia Heinrich, Thomas Austgen, Darko Castven, Moritz Hess, Christian Labenz, Martha Kirstein, Carolin Zimpel, Lena Stockhoff, Benjamin Maasoumy, Bernd Heinrich, Hans Heinrich Wedemeyer, Peter Robert Galle, Harald Binder, Marc Nguyen‐Tat, Jens Uwe Marquardt. Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome. United European Gastroenterology Journal 2023; 11(1): 92 doi: 10.1002/ueg2.12337
|
| 65 |
Naim Alkhouri, Ariel E. Feldstein. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. Metabolism 2016; 65(8): 1087 doi: 10.1016/j.metabol.2016.01.013
|
| 66 |
Andrew J Fowell, Kirsty Fancey, Karen Gamble, Kelly Bicknell, Joanna K Dowman, Paul Howden, Richard J Aspinall. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. Frontline Gastroenterology 2021; 12(2): 102 doi: 10.1136/flgastro-2019-101304
|
| 67 |
Maurizio Soresi, Lydia Giannitrapani, Melchiorre Cervello, Anna Licata, Giuseppe Montalto. Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology 2014; 20(48): 18131-18150 doi: 10.3748/wjg.v20.i48.18131
|
| 68 |
Mohammad Safarian, Sepideh Mohammadpour, Mojtaba Shafiee, Azita Ganji, Anvar Soleimani, Mohsen Nematy, Ali Bahari. Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13(2): 989 doi: 10.1016/j.dsx.2019.01.005
|
| 69 |
Arturo Gonzalez‐Quintela, Santiago Tomé, Carmen Fernandez‐Merino, Jesus Rey, Luis Meijide, Francisco Gude. Synergistic Effect of Alcohol Consumption and Body Mass on Serum Concentrations of Cytokeratin‐18. Alcoholism: Clinical and Experimental Research 2011; 35(12): 2202 doi: 10.1111/j.1530-0277.2011.01570.x
|
| 70 |
David E. Amacher. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 2014; 19(7): 541 doi: 10.3109/1354750X.2014.958535
|
| 71 |
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine 2011; 43(8): 617 doi: 10.3109/07853890.2010.518623
|
| 72 |
Yusuf Yilmaz, Fatih Eren. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2014; 26(11): 1292 doi: 10.1097/MEG.0000000000000184
|
| 73 |
Diana Joka, Kristin Wahl, Sarah Moeller, Jerome Schlue, Bernhard Vaske, Matthias J. Bahr, Michael P. Manns, Klaus Schulze-Osthoff, Heike Bantel. Prospective Biopsy-Controlled Evaluation of Cell Death Biomarkers for Prediction of Liver Fibrosis and Nonalcoholic Steatohepatitis. Hepatology 2012; 55(2): 455 doi: 10.1002/hep.24734
|
| 74 |
J. K. Dowman, J. W. Tomlinson, P. N. Newsome. Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2011; 33(5): 525 doi: 10.1111/j.1365-2036.2010.04556.x
|
| 75 |
Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Current Obesity Reports 2024; 13(3): 510 doi: 10.1007/s13679-024-00574-z
|
| 76 |
M. Civera, A. Urios, M. L. Garcia‐Torres, J. Ortega, J. Martinez‐Valls, N. Cassinello, J. A. del Olmo, A. Ferrandez, J. M. Rodrigo, C. Montoliu. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes/Metabolism Research and Reviews 2010; 26(3): 187 doi: 10.1002/dmrr.1070
|
| 77 |
Kai Liu, Jinli Lou, Tao Wen, Jiming Yin, Bin Xu, Wei Ding, Anna Wang, Daojie Liu, Chao Zhang, Dexi Chen, Ning Li. Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM‐induced autophagy or BAX. Liver International 2013; 33(10): 1566 doi: 10.1111/liv.12238
|
| 78 |
Ariel E Feldstein, Naim Alkhouri, Rita De Vito, Anna Alisi, Rocio Lopez, Valerio Nobili. Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children. American Journal of Gastroenterology 2013; 108(9): 1526 doi: 10.1038/ajg.2013.168
|
| 79 |
Pamela Valva, Daniela Rios, Paola Casciato, Adrián Gadano, Omar Galdame, Eduardo Mullen, Gustavo Bertot, Elena de Matteo, María V. Preciado. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina. European Journal of Gastroenterology & Hepatology 2018; 30(6): 637 doi: 10.1097/MEG.0000000000001079
|
| 80 |
María Rubio-Murillo, Alejandro Rodríguez-Martínez. NAFLD and NASH. 2020; : 69 doi: 10.1007/978-3-030-37173-9_5
|
| 81 |
Pamela Valva, Elena De Matteo, María C. Galoppo, María I. Gismondi, María V. Preciado. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. Journal of Medical Virology 2010; 82(6): 949 doi: 10.1002/jmv.21699
|
| 82 |
Mitchell R. McGill, Benjamin L. Woolbright, James L. Weemhoff, Hartmut Jaeschke. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017; : 71 doi: 10.1007/978-94-007-7675-3_5
|
| 83 |
Eugenia Tsai, Tai-Ping Lee. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clinics in Liver Disease 2018; 22(1): 73 doi: 10.1016/j.cld.2017.08.004
|
| 84 |
Raj Vuppalanchi, Naga Chalasani. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2009; 49(1): 306 doi: 10.1002/hep.22603
|
| 85 |
Masaru Tsutsui, Naoki Tanaka, Masatomo Kawakubo, Yo Sheena, Akira Horiuchi, Michiharu Komatsu, Tadanobu Nagaya, Satoru Joshita, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Toshifumi Aoyama, Eiji Tanaka, Kenji Sano. Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology 2010; 44(6): 440 doi: 10.1097/MCG.0b013e3181bdefe2
|
| 86 |
Jing Chen, Yueyong Zhu, Qi Zheng, Jiaji Jiang. Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis. Hepatology Research 2014; 44(8): 854 doi: 10.1111/hepr.12197
|
| 87 |
Y. Yilmaz. Letter: diagnostic accuracy of M30 levels for identifying patients with non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2013; 37(2): 283 doi: 10.1111/apt.12142
|
| 88 |
Bryan D. Maliken, James E. Nelson, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Kris V. Kowdley. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013; 57(5): 1806 doi: 10.1002/hep.26238
|
| 89 |
Mitchell R. McGill, Benjamin L. Woolbright, James L. Weemhoff, Hartmut Jaeschke. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_5-1
|
| 90 |
Dulshan Jayasekera, Phillipp Hartmann. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease. World Journal of Hepatology 2023; 15(5): 609-640 doi: 10.4254/wjh.v15.i5.609
|
| 91 |
Hazem Abd-Elgawad, Nashwa Abu-Elsaad, Amr El-Karef, Tarek Ibrahim. Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis. Canadian Journal of Physiology and Pharmacology 2016; 94(7): 779 doi: 10.1139/cjpp-2016-0001
|
| 92 |
Sezgin Ulukaya, Engin Ulukaya, Isik Alper, Arzu Yilmaztepe‐Oral, Murat Kilic. Soluble cytokeratin 18 biomarkers may provide information on the type of cell death during early ischemia and reperfusion periods of liver transplantation. Clinical Transplantation 2010; 24(6): 848 doi: 10.1111/j.1399-0012.2009.01177.x
|
| 93 |
Fatih Eren, Yusuf Yilmaz, Sukran Kose, Filiz Ture Ozdemir, Oya Yonal, Ramazan Kurt, Osman Ozdogan, Erol Avsar. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clinica Chimica Acta 2010; 411(23-24): 2029 doi: 10.1016/j.cca.2010.08.035
|
| 94 |
Joanne R. Morling, Jonathan A. Fallowfield, Rachel M. Williamson, Lisa D. Nee, Andrew P. Jackson, Stephen Glancy, Rebecca M. Reynolds, Peter C. Hayes, Indra N. Guha, Mark W. J. Strachan, Jackie F. Price. Non‐invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Liver International 2014; 34(8): 1267 doi: 10.1111/liv.12385
|
| 95 |
Ariel E. Feldstein, Anna Wieckowska, Rocio A. Lopez, Yao-Chang Liu, Nizar N. Zein, Arthur J. McCullough. Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis. Hepatology 2009; 50(4): 1072 doi: 10.1002/hep.23050
|
| 96 |
Jeffrey R. Lewis, Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and Update. Digestive Diseases and Sciences 2010; 55(3): 560 doi: 10.1007/s10620-009-1081-0
|
| 97 |
Danielle Adebayo, Vincenzo Morabito, Fausto Andreola, Giulia Pieri, Tu‐Vin Luong, Amar Dhillon, Rajeshwar Mookerjee, Rajiv Jalan. Mechanism of cell death in acute‐on‐chronic liver failure: a clinico‐pathologic‐biomarker study. Liver International 2015; 35(12): 2564 doi: 10.1111/liv.12850
|
| 98 |
Miwa Kawanaka, Ken Nishino, Jun Nakamura, Noriyo Urata, Takahito Oka, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro Yamada. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Annals of Hepatology 2015; 14(6): 837 doi: 10.5604/16652681.1171767
|
| 99 |
Ankita Singh, Vipul Ranjan, Rina Das, Karun Bhatti, Dinesh Kumar Mehta, Ram Mohan Chidurala. Serum Biomarkers for Noninvasive Diagnosis of Liver Diseases: How Laudable are These Tools?. Current Chemical Biology 2021; 15(2): 128 doi: 10.2174/2212796814999201111204639
|
| 100 |
Shiori Sugawara, Takemi Akahane, Kennichi Fukui, Ikuyo Tsukamoto. Association of Serum CK18 M30 Antigen Level with Food Intake in Middle-aged Japanese Men. Nippon Eiyo Shokuryo Gakkaishi 2014; 67(3): 127 doi: 10.4327/jsnfs.67.127
|
| 101 |
Mesbah Uddin Ahmed. Association of Serum Cytokeratin-18 Fragment Concentration in Patients with Different Types of Nonalcoholic Fatty Liver Disease. Gastroenterology & Hepatology : Open Access 2015; 2(2) doi: 10.15406/ghoa.2015.02.00037
|
| 102 |
Steven J. Potts, Johanna K. DiStefano. Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. Methods in Pharmacology and Toxicology 2014; : 101 doi: 10.1007/7653_2014_29
|
| 103 |
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels #. Hepatology 2009; 49(2): 697 doi: 10.1002/hep.22691
|
| 104 |
|
| 105 |
Luca Maccioni, Yves Horsmans, Isabelle Leclercq, Bernd Schnabl, Peter Stärkel. Serum keratin 18‐M65 levels detect progressive forms of alcohol‐associated liver disease in early noncirrhotic stages. Alcohol: Clinical and Experimental Research 2023; 47(6): 1079 doi: 10.1111/acer.15081
|
| 106 |
Vlad Ratziu, Laurence Martin, Larysa Fedchuk, Thierry Poynard. Can Nonalcoholic Steatohepatitis be Diagnosed Without Liver Biopsy?. Biomarkers in Medicine 2009; 3(4): 353 doi: 10.2217/bmm.09.36
|
| 107 |
R. Kwok, Y.‐K. Tse, G. L.‐H. Wong, Y. Ha, A. U. Lee, M. C. Ngu, H. L.‐Y. Chan, V. W.‐S. Wong. Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments. Alimentary Pharmacology & Therapeutics 2014; 39(3): 254 doi: 10.1111/apt.12569
|
| 108 |
Guofeng Ding, Zhi Li, Lei Zhang, Hui Ma, Hui Li. Circulating full‐length cytokeratin 18 for predicting prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure patients with lamivudine treatment. Hepatology Research 2016; 46(4): 329 doi: 10.1111/hepr.12549
|
| 109 |
|
| 110 |
Sudeep Tanwar, Paul M. Trembling, Indra N. Guha, Julie Parkes, Philip Kaye, Alastair D. Burt, Stephen D. Ryder, Guruprasad P. Aithal, Christopher P. Day, William M. Rosenberg. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013; 57(1): 103 doi: 10.1002/hep.26030
|
| 111 |
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 2011; 9(3): 321 doi: 10.1586/erc.11.15
|
| 112 |
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. Journal of Gastroenterology and Hepatology 2011; 26(s1): 153 doi: 10.1111/j.1440-1746.2010.06547.x
|
| 113 |
Dina G. Tiniakos, George V. Papatheodoridis. Serum Markers of Hepatocyte Apoptosis: Current Terminology and Predictability in Clinical Practice. Hepatology 2010; 51(2): 717 doi: 10.1002/hep.23251
|
| 114 |
Angeliki Papachristodoulou, Dimitrios Kavvadas, Athanasios Karamitsos, Theodora Papamitsou, Maria Chatzidimitriou, Antonia Sioga. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?. Pediatric Reports 2021; 13(2): 312 doi: 10.3390/pediatric13020039
|
| 115 |
M. H. Miller, J. F. Dillon. Commentary: assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology & Therapeutics 2013; 37(2): 275 doi: 10.1111/apt.12134
|
| 116 |
Pauline Verhaegh, Roisin Bavalia, Bjorn Winkens, Ad Masclee, Daisy Jonkers, Ger Koek. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018; 16(6): 837 doi: 10.1016/j.cgh.2017.08.024
|
| 117 |
Steven G Pearce, Nirav C Thosani, Jen-Jung Pan. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-7
|
| 118 |
Zeynep Hünkerler, Tülay Köken, Buğra Koca, Ahmet Kahraman. Role of Uremic Toxins on Apoptosis With Varying Periods of Hemodialysis. Therapeutic Apheresis and Dialysis 2017; 21(1): 38 doi: 10.1111/1744-9987.12504
|
| 119 |
Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li. Cytokeratin 18 in nonalcoholic fatty liver disease: value and application. Expert Review of Molecular Diagnostics 2024; : 1 doi: 10.1080/14737159.2024.2413941
|
| 120 |
Ancha Baranova, Zobair M. Younossi. Reply to the Letter to the Editor: “A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments” by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. Obesity Surgery 2008; 18(11): 1509 doi: 10.1007/s11695-008-9641-5
|
| 121 |
George V. Papatheodoridis, Emilia Hadziyannis, Emmanuel Tsochatzis, Anastasia Georgiou, Georgia Kafiri, Dina G. Tiniakos, Katerina Margariti, Spilios Manolakopoulos, Emanuel K. Manesis, Athanasios J. Archimandritis. Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2010; 44(4): e87 doi: 10.1097/MCG.0b013e3181c0945a
|
| 122 |
A. Gonzalez-Quintela, I. Abdulkader, J. Campos, L. Fernandez-Hernandez, S. Lojo. Serum Levels of Keratin-18 Fragments [Tissue Polypeptide-Specific Antigen (TPS)] Are Correlated with Hepatocyte Apoptosis in Alcoholic Hepatitis. Digestive Diseases and Sciences 2009; 54(3): 648 doi: 10.1007/s10620-008-0371-2
|
| 123 |
Mitchell R. McGill, Hartmut Jaeschke. Drug-induced Liver Injury. Advances in Pharmacology 2019; 85: 221 doi: 10.1016/bs.apha.2019.02.001
|
| 124 |
Iradj Maleki, Mahmood Reza Aminafshari, Tarang Taghvaei, Vahid Hosseini, Alireza Rafiei, Zhila Torabizadeh, Maryam Barzin, Elahe Orang. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World Journal of Gastroenterology 2014; 20(35): 12566-12573 doi: 10.3748/wjg.v20.i35.12566
|
| 125 |
Helena Cortez-Pinto, Mariana Machado. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2008; 2(2): 217 doi: 10.1586/17474124.2.2.217
|
| 126 |
Karel Dvorak, Jan Stritesky, Jaromir Petrtyl, Libor Vitek, Renata Sroubkova, Martin Lenicek, Vaclav Smid, Martin Haluzik, Radan Bruha, Pavel Strnad. Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control Study. PLoS ONE 2014; 9(10): e111551 doi: 10.1371/journal.pone.0111551
|
| 127 |
Andreas E Kremer, Christian Rust, Peter Eichhorn, Ulrich Beuers, Stefan Holdenrieder. Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Review of Molecular Diagnostics 2009; 9(2): 139 doi: 10.1586/14737159.9.2.139
|
| 128 |
Mikako Obika, Hirofumi Noguchi. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research 2012; 2012: 1 doi: 10.1155/2012/145754
|
| 129 |
Yusuf Yilmaz. “Defragmenting” the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18 #. Hepatology 2009; 50(3): 990 doi: 10.1002/hep.23065
|
| 130 |
Matt Cave, Keith Cameron Falkner, Latasha Henry, Brittany Costello, Bonnie Gregory, Craig J. McClain. Serum Cytokeratin 18 and Cytokine Elevations Suggest A High Prevalence of Occupational Liver Disease in Highly Exposed Elastomer/Polymer Workers. Journal of Occupational & Environmental Medicine 2011; 53(10): 1128 doi: 10.1097/JOM.0b013e31822cfd68
|
| 131 |
S Lefere, F Van de Velde, L Devisscher, M Bekaert, S Raevens, X Verhelst, Y Van Nieuwenhove, M Praet, A Hoorens, C Van Steenkiste, H Van Vlierberghe, B Lapauw, A Geerts. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. International Journal of Obesity 2017; 41(8): 1207 doi: 10.1038/ijo.2017.102
|
| 132 |
Yusuf Yilmaz, Ramazan Kurt. Is M65 Really Better Than M30 as a Biomarker of Hepatic Fibrosis?. Hepatology 2012; 55(2): 654 doi: 10.1002/hep.25520
|
| 133 |
Lei Fu, Nurdan Guldiken, Katharina Remih, Anna Sophie Karl, Christian Preisinger, Pavel Strnad. Serum/Plasma Proteome in Non-Malignant Liver Disease. International Journal of Molecular Sciences 2024; 25(4): 2008 doi: 10.3390/ijms25042008
|
| 134 |
Gerald Denk, Ahmed‐Jawid Omary, Florian Paul Reiter, Simon Hohenester, Ralf Wimmer, Stefan Holdenrieder, Christian Rust. Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatology Research 2014; 44(13): 1286 doi: 10.1111/hepr.12304
|